

# Crohn's disease adult – continuing authority application

## When to use this form

Use this form to apply for **continuing** PBS-subsidised biological medicines for patients 18 years or over with severe Crohn's disease.

## Important information

**Continuing** authority applications must be in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Applications for **balance of supply** can be made in real time using the **Online PBS Authorities** system or by phone. Call 1800 700 270 Monday to Friday, 8 am to 5 pm, local time.

Under no circumstances will phone approvals be granted for severe Crohn's disease **continuing** authority applications.

Where the term 'biological medicine' appears, it refers to adalimumab, infliximab, upadacitinib, ustekinumab or vedolizumab.

The information in this form is correct at the time of publishing and may be subject to change.

## Continuing treatment

This form is ONLY for **continuing** treatment.

After a written authority application for the **first continuing** treatment has been approved, **subsequent continuing** treatments with PBS-subsidised biosimilar brands of biological medicines are **Authority Required (STREAMLINED)** and do not require authority approval from Services Australia for the listed quantity and repeats.

## Section 100 arrangements for infliximab i.v. and vedolizumab i.v.

These items are available to a patient who is attending:

- an approved private hospital, **or**
- a public hospital

**and** is a:

- day admitted patient
- non-admitted patient, **or**
- patient on discharge.

These items are not available as a PBS benefit for in-patients of a public hospital.

The hospital name and provider number must be included in this authority form.

## Treatment specifics

The assessment of the patient's response to the course of treatment must be conducted within the time frame specified in the restriction. Where a demonstration of response is not conducted within the required time frame, the patient will be deemed to have failed treatment with that particular PBS-subsidised biological medicine.

A patient who has experienced a serious adverse reaction of a severity necessitating permanent treatment withdrawal is not considered to have failed treatment with that particular PBS-subsidised biological medicine.

## For more information

Go to [servicesaustralia.gov.au/healthprofessionals](https://servicesaustralia.gov.au/healthprofessionals)



**14** The patient has demonstrated or sustained an adequate response to treatment with this drug evidenced by:

- ☐ a reduction in the Crohn's Disease Activity Index (CDAI) score to a level  $\leq 150$  if assessed by CDAI or if affected by extensive small intestine disease

CDAI score

Date of assessment (no more than 4 weeks old)  
(DD MM YYYY)

--	--	--	--	--	--

or

- ☐ an improvement of intestinal inflammation as demonstrated by at least one of the following:

- ☐ blood: normalisation of the platelet count
- ☐ blood: erythrocyte sedimentation rate (ESR)  $\leq 25$  mm/hour
- ☐ blood: C-reactive protein (CRP)  $\leq 15$  mg/L
- ☐ faeces: normalisation of lactoferrin or calprotectin level
- ☐ evidence of mucosal healing, as demonstrated by diagnostic imaging findings, compared to the baseline assessment

or

- ☐ reversal of high faecal output state

or

- ☐ avoidance of the need for surgery or total parenteral nutrition (TPN) if affected by short gut syndrome, extensive small intestine disease or is an ostomy patient

or (for upadacitinib 30mg ONLY)

- ☐ the condition has not met the improvements specified above due to the prescribed dose of 15mg being too low - this authority application seeks higher dosing of 30mg.

## Checklist

**15**  The relevant attachments need to be provided with this form.

- ☐ Details of the proposed prescription(s).
- ☐ The relevant pathology reports, diagnostic imaging test(s) and/or the completed Adult Crohn's Disease Activity Index calculation sheet.

## Privacy notice

**16** Personal information is protected by law (including the *Privacy Act 1988*) and is collected by Services Australia for the purposes of assessing and processing this authority application.

Personal information may be used by Services Australia, or given to other parties where the individual has agreed to this, or where it is required or authorised by law (including for the purpose of research or conducting investigations).

More information about the way in which Services Australia manages personal information, including our privacy policy, can be found at [servicesaustralia.gov.au/privacypolicy](https://servicesaustralia.gov.au/privacypolicy)

## Prescriber's declaration

You do not need to **sign** the declaration if you complete this form using Adobe Acrobat Reader and return this form through Health Professional Online Services (HPOS) at [servicesaustralia.gov.au/hpos](https://servicesaustralia.gov.au/hpos)

### 17 I declare that:

- I am aware that this patient must meet the criteria listed in the current Schedule of Pharmaceutical Benefits to be eligible for this medicine
- I have informed the patient that their personal information (including health information) will be disclosed to Services Australia for the purposes of assessing and processing this authority application
- I have provided details of the proposed prescription(s) and the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction
- the information I have provided in this form is complete and correct.

### I understand that:

- giving false or misleading information is a serious offence.

☐ I have read, understood and agree to the above.

Date (DD MM YYYY) (you **must** date this declaration)

--	--	--	--	--	--

Prescriber's signature (**only** required if returning by post)



## Returning this form

Return this form, details of the proposed prescription(s) and any relevant attachments:

- online** (no signature required), upload through HPOS at [servicesaustralia.gov.au/hpos](https://servicesaustralia.gov.au/hpos)
- or
- by post (signature required) to  
Services Australia  
Complex Drugs Programs  
Reply Paid 9826  
HOBART TAS 7001

Week ending (DD MM YYYY)

Each parameter in this table must be assigned a value.

			Factor	Subtotal
<b>Liquid stools</b> (cumulative total over the last 7 days)	Number of liquid or soft stools over the last 7 days	sum =	x 2	
	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>			
<b>Abdominal pain †</b> (cumulative total over the last 7 days)	Daily assessment †	sum =	x 5	
	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>			
<b>General well being ‡</b> (cumulative total over the last 7 days)	Daily assessment ‡	sum =	x 7	
	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>			
<b>Extra-intestinal</b>				
Arthritis/arthralgia	None = 0	score =	x 20	
	Yes = 1			
Iritis/uveitis	None = 0	score =	x 20	
	Yes = 1			
Skin/mouth lesions	None = 0	score =	x 20	
	Yes = 1			
Peri-anal disease	None = 0	score =	x 20	
	Yes = 1			
Other fistula	None = 0	score =	x 20	
	Yes = 1			
Fever > 37.8°C	None = 0	score =	x 20	
	Yes = 1			
<b>Anti-diarrhoeals</b>	None = 0	score =	x 30	
	Yes = 1			
<b>Abdominal mass</b>	None = 0	score =	x 10	
	Questionable = 2			
	Definite = 5			
<b>Haematocrit (Hct)</b>	Males (47 – Hct)	score =	x 6	
	Females (42 – Hct)	score =	x 6	
<b>Weight</b> (Maximum deduction of -10 for overweight patients)	Standard kg	kg	100 x $\left(1 - \frac{\text{current}}{\text{standard}}\right)$	
	Current kg	kg		
<b>TOTAL CDAI SCORE</b>				

† <b>Abdominal pain</b>	None = 0
	Intermediate = 1 or 2
	Severe = 3
‡ <b>General well being</b>	Well = 0
	Intermediate = 1, 2 or 3
	Terrible = 4